The record
| Class | mitochondrial |
|---|---|
| Also known as | Elamipretide, MTP-131, Bendavia, Forzinity |
| Chain length | - |
| Molecular weight | 639.8 Da |
| Half-life | 2 hours (SC); 5 min (IV - true elimination) |
| Route | SC or IV |
| Studied for | Barth syndrome (FDA approved 2025); Heart failure (investigational); Mitochondrial myopathies; Age-related macular degeneration |
| Research use | Mitochondrial dysfunction models; Ischemia-reperfusion injury; Sarcopenia/muscle aging |
| What has been shown | Improves muscle strength in Barth syndrome; Enhances ATP production; Reduces oxidative stress; Improves exercise tolerance in aged subjects |
| How it works | Mitochondria-targeting tetrapeptide that selectively binds to cardiolipin in the inner mitochondrial membrane. Stabilizes electron transport chain complexes, reduces electron leakage and ROS production, enhances ATP synthesis. Inhibits cytochrome c peroxidase activity. Does not affect normal mitochondria - only improves dysfunctional ones. |
| Patent status | patented |
| Regulatory status | approved (Barth syndrome) |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Mitochondrial Efficiency / Energy Signaling (affection, 56%)
- Oxidative Stress Resilience (affection, 80%)
- Acetaminophen toxicity (illness, 60%)
- Age-related macular degeneration (illness, 100%)
- Antioxidant supplementation (illness, 60%)
- Barth syndrome (illness, 100%)
- Detoxification support (illness, 60%)
- Erythropoietic protoporphyria - FDA approved (illness, 30%)
- Heart failure (illness, 100%)
- Mitochondrial myopathies (illness, 100%)
- Polymorphous light eruption (illness, 30%)
- Skin lightening (illness, 60%)
- Solar urticaria (illness, 30%)
- Vitiligo (illness, 30%)
- Fatigue or low energy (symptom, 67%)